As Transdermal Drug Delivery Gains Acceptance, Market Shoots to $7.9 Billion

New York, April 13, 2007— With new biological therapeutic treatments being developed at a record pace, their potential could be compromised by the lack of adequate drug delivery systems. Consequently, transdermal and transmucosal delivery systems, with their ability to deliver substantial amounts of drugs over a long period of time, are a hot commodity with 2006 revenues reaching $6.7 billion. According to Drug Delivery Markets, Vol. IV: Transdermal and Transmucosal Delivery Systems, a new report from market research firm Kalorama Information, increasing acceptance of such delivery as a preferred method of administration will push the market to nearly $7.9 billion by 2010.

Twelve years after the transdermal nicotine patch was approved in the U.S. for over-the-counter sale, the acceptance and popularity of this form of drug delivery has created a transdermal drug delivery segment totaling $5.7 billion in 2006.

More recent market growth has been driven by an increase in biotechnology drugs that require novel delivery technologies. At the same time, continued demand for nicotine patches, hormone therapies, pain relief and other treatments contributed substantially to the rise of pharmaceuticals utilizing transdermal drug delivery systems, as well as the delivery systems themselves.

“The move in the industry is to greatly capitalize on easier methods of administration of drugs to maintain patient compliance and for administration of products that eliminate possibilities of contamination and infection. Yet challenges abound, and oral delivery still dominates the marketplace,” states Mary Anne Crandall, the report’s author. “However, we expect that continued research will likely break down the barriers that limit the types of drug molecules that may be delivered through the skin, thus opening up this market to even greater potential for growth.”

Transdermal and Transmucosal Delivery Systems provides an all-inclusive market overview including a look at pharmaceutical-only and technology-only segments. The report offers an extensive look at promising developments in the market, key players in the industry, market forecasts and outlook through 2010, and challenges facing the industry. It is available from Kalorama Information by visiting http://www.kaloramainformation.com/ Drug-Delivery-Vol-1399440. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest independent market research on medical markets. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.